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Grafting of methoxypoly(ethylene glycol) (mPEG) to cells and biomaterials is a promising non-pharmacological immunomod-
ulation technology. However, due to the labile nature of cells, surface-plasma interactions are poorly understood; hence, a latex 
bead model was studied. PEGylation of beads resulted in a density and molecular weight dependent decrease in total adsorbed 
protein with a net reduction from (159.9±6.4) ng cm2 on bare latex to (18.4±0.8) and (52.3±5.3) ng cm2 on PEGylated beads 
(1 mmol L1 of 2 or 20 kD SCmPEG, respectively). SDS-PAGE and iTRAQ-MS analysis revealed differential compositions of 
the adsorbed protein layer on the PEGylated latex with a significant reduction in the compositional abundance of proteins in-
volved in immune system activation. Thus, the biological efficacy of immunocamouflaged cells and materials is mediated by 
both biophysical obfuscation of antigens and reduced surface-macromolecule interactions.   
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An increasing number of diverse and broad ranging clinical 
interventions utilize biologically derived products and/or 
biomaterials as therapeutic agents. Traditional biological 
products include blood and blood components and do-
nor-derived tissues for transplantation while newer biologi-
cals encompass purified proteins, cell-based therapies and, 
potentially, gene therapy. Biomaterials, which can be natu-
ral or synthetic, are increasingly used in medical devices 
that interface with biological systems such as replacement 
joints, stents and catheters [1,2]. However, for all of these 
materials, biocompatibility is a key issue, and prevention of 
immune recognition and subsequent host responses is cru-
cial to avoid failure of the therapy and serious medical con-
sequences.  
To achieve biocompatibility, biomaterials are often sur-
face-modified in order to minimize protein interaction and 
protein adsorption to the material, thus attenuating immune 
recognition and rendering the surface ‘non-fouling’. A sim-
ilar concept of immunomodulation can be applied to bio-
logical products. Immunocamouflage of cells and tissues 
refers to the biophysical and biological camouflage of cell 
surfaces from interaction with other cells, macromolecules 
and viruses [3–6]. This “biomaterials” approach for tissue 
engineering has emerged as a promising technique for pre-
venting allorecognition of foreign cells, particularly in the 
context of transfusion and transplantation medicine. Im-
munocamouflage of cells is produced by the covalent graft-
ing of methoxypoly(ethylene glycol) (mPEG; PEGylation), 
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or other low immunogenic polymers, to proteins expressed 
on the cell membrane. Consequent to grafting, the polymer 
camouflages both antigenic sites and surface charge attenu-
ating the risk of immune recognition. This non-pharma-     
cological technology holds great promise in preventing 
immunological rejection of transplanted cells and tissues 
without the inherent toxicity and health risks associated 
with currently used immunosuppressive therapies. Indeed, 
this tissue bioengineering approach has been experimentally 
shown to prevent antibody binding, reduce allorecognition 
and immunogenicity and to effectively block recep-
tor-ligand interactions necessary for viral invasion while 
having minimal effects on cell viability and function [6].  
However, due to the labile nature of biological cells, the 
effects of the grafted polymer on cell-plasma interactions 
have not been fully elucidated. To more fully examine the 
effect of polymer grafting on surface-macromolecule inter-
actions between blood plasma and the surface of both bio-
logical cells and biomaterials, a latex bead (1.2 or 8.0 m 
diameter) model was utilized. The effects of mPEG grafting 
concentration and molecular weight on total as well as spe-
cific plasma protein adsorption to the latex surface were 
examined via flow cytometry, quantitative protein assay, 
and sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE). Moreover, more detailed studies were 
carried out using isobaric tags for relative and absolute 
quantitation (iTRAQ) labeling followed by mass spectrom-
etry (MS) to directly assess differential plasma protein ad-
sorption to unmodified and PEGylated latex bead surfaces. 
The results of these studies have provided significant new 
information on the interaction between human plasma and 
mPEG-bioengineered surfaces.  
1  Materials and methods 
1.1  Latex bead model and polymer grafting 
To investigate the effect of PEGylation on plasma pro-
tein-surface interactions, aliphatic amine polystyrene latex 
beads (1.2 and 8.0 m in diameter; Molecular Probes, Invi-
trogen, Carlsbad, CA, USA) were used. As shown in Figure 1, 
the bead consists of a hydrophobic polystyrene core and is 
negatively charged due to carboxyl groups (COO). The 
surface of the latex particles is functionalized with primary 
amine (NH3
+) groups covalently attached to the latex core 
via a six-carbon aliphatic arm with an average of 3.5×107 
residues per bead. These primary amine groups are the sites 
used for the covalent grafting of the activated mPEG poly-
mer.  
Activated succinimidyl carbonate methoxypoly(ethylene 
glycol) (SC-mPEG) (Laysan Bio, Inc., Arab, AL, USA) was 
dissolved in PEG buffer (50 mmol L1 K2HPO4, 105 mmol 
L1 NaCl, pH 8.0) and added to a 2.0 weight percent (% w/v) 
aqueous suspension of aliphatic amine polystyrene latex 
particles to reach the desired final mPEG grafting concen-
tration (0–5 mmol L1). Samples were incubated for 60 min 
at room temperature with constant mixing and subsequently  
 
 
Figure 1  Latex bead model. Aliphatic amine polystyrene latex particles were utilized for plasma protein adsorption assays. The core of the particle is nega-
tively charged and composed of hydrophobic polystyrene. The surface of the latex is functionalized with aliphatic primary amine groups. The number of 
positively charged amine groups is in large excess to the number of negatively charged carboxyl groups in the latex core imparting an overall positive charge 
to the particle. Approximately 3.5×107 and 7.6×109 amine groups are present on the 1.2 and 8.0 diameter µm particles, respectively. These primary amine 
groups on the latex particles (or membrane protein lysine residues) act as nucleophiles in an SN1 substitution reaction, releasing the free N-hydroxy succin-
imide linker group and forming a covalent bond between the polymer and bead. SC-mPEG forms a carbamate (urethane) bond while SPA- and SVA-mPEG  
form an amide bond. 
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washed five times to remove unbound mPEG. As shown in 
Figure 1, SC-mPEG grafting resulted in a carbamate linkage 
between the mPEG polymer and the bead with a by-product 
of N-hydroxy succinimide that was subsequently removed 
via washing. A final aqueous latex suspension was made 
(2.0% w/v) and stored at 4°C for the subsequent experi-
ments.  
1.2  Plasma adsorption to and desorption from control 
and modified latex 
Following informed consent, whole blood from healthy 
volunteers was collected into EDTA anticoagulant vacu-
tainer tubes. Human plasma was obtained by centrifugation 
at 1000×g (22°C; 5 min). Plasma protein adsorption studies 
were carried out using both unlabeled and fluorescently 
labeled plasma.  
All results were expressed as mean±standard error of the 
mean (SEM). A minimum of three replicate experiments 
was performed for all studies. Statistical analyses were done 
using SPSS v.16.0 statistical software (Statistical Products 
and Services Solutions, SPSS Inc., Chicago, IL, USA). For 
comparison of three or more mean values, a one-way analy-
sis of variance (ANOVA) was performed followed by a 
Tukey post-hoc test for pair-wise comparisons of means. 
Significance was determined by a two-tailed P-value<0.05. 
1.3  Plasma protein labeling, adsorption and desorption 
studies 
Unlabeled plasma protein adsorption experiments were 
performed in a 50% plasma-latex suspension (500 cm2 total 
latex surface area). Fluorescent plasma protein adsorption 
studies were conducted on 83.3 cm2 latex using 83.3% (di-
luted with unlabeled plasma) Alexa 488 (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA) labeled plasma. Bare and 
differentially modified beads were incubated with plasma 
(unlabeled or fluorescent) for 60 min at room temperature 
with constant mixing. Following adsorption, samples were 
washed five times in 0.02 mol L1 phosphate buffer with 3 
mmol L1 NaN3 (pH 7.4) to remove unbound protein. 
Latex samples with adsorbed fluorescent protein were 
evaluated via microscopic analysis and flow cytometry (BD 
FACSCalibur, BD Biosciences, San Jose, CA, USA) to 
qualitatively and quantitatively assess the adsorbed protein. 
Data acquisition and analysis were performed using 
CellQuest Pro software (BD Biosciences, San Jose, CA, 
USA) and excitation and emission wavelengths of 488 nm 
and 530 nm, respectively. A minimum of 20000 events was 
collected per sample.   
Bound proteins were desorbed from bare control and 
differentially modified PEGylated latex beads by the addi-
tion of solubilization buffer (2% sodium dodecyl sulfate 
(SDS) and 80 mmol L1 dithiothreitol (DTT) in water) and 
incubated for 5 min in a 95°C water bath. Latex samples 
were centrifuged for 5 min at 16000×g and the supernatants 
containing desorbed unlabeled proteins were subjected to 
colorimetric protein assay, SDS-PAGE, and mass spec-
trometry analysis. Following desorption of fluorescent pro-
tein, latex beads were evaluated via flow cytometry (as de-
scribed above) to estimate the level of residual fluorescence 
due to “permanently” adsorbed fluorescent protein. 
1.4  Quantitative protein assay 
Unlabeled proteins were desorbed from 500 cm2 of latex 
surface with 70 L of solubilization buffer. Duplicate 25 L 
samples of solubilized desorbed protein were subjected to 
colorimetric protein assay (RC DC protein assay, Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) according to manu-
facturer’s instructions. For each assay, a standard curve was 
constructed using a bovine serum albumin (BSA) solution 
(2.0 mg mL1, Thermo Fisher Scientific, Inc., Rockford, IL, 
USA).  
1.5  SDS-PAGE analysis 
Unlabeled proteins desorbed from control and PEGylated 
latex beads were analyzed by SDS-PAGE as described by 
Laemmli [7]. Identical volumes of desorbed proteins and 
control solutions were loaded onto a 7% polyacrylamide gel. 
Electrophoresis was performed at room temperature, 25 mA 
current, for 60 min. Each gel included lanes containing: 
sample buffer only; molecular weight standards (Kaleido-
scope precision plus protein standards; Bio-Rad Laborato-
ries, Inc., Hercules, CA, USA); and 100 times diluted neat 
human plasma in sample buffer. Following SDS-PAGE, gel 
was stained with Pierce ImperialTM protein stain (Thermo 
Fisher Scientific, Inc., Rockford, IL, USA).  
1.6  iTRAQ and mass spectrometry 
Based on the protein assay data, 200 g of unlabeled protein 
was desorbed from an estimated amount of latex using 200 
µL of desorption buffer. The supernatants containing de-
sorbed protein were submitted to the University of Victoria 
Proteomics Centre (www.proteincentre.com) for iTRAQ 
labeling and MS analysis. Briefly, four protein samples de-
sorbed from four differentially modified latex particle prep-
arations (0 (control), 0.5, 2.0 and 5.0 mmol L1), were di-
gested with trypsin and labeled with the iTRAQTM reagent 
(Applied Biosystems, Foster City, CA, USA). Differentially 
labeled peptides were subjected to liquid chromatography 
followed by tandem mass spectrometry (LC-MS/MS) anal-
ysis using an integrated Famos autosampler, a SwitchosII 
switching pump and an UltiMate micro pump (LC Pack-
ings––A Dionex Company, Sunnyvale, CA, USA). The 
system was equipped with a Hybrid Quadrupole-Time of 
Flight (TOF) LC/MS/MS mass spectrometer (QStar, Mary 
Esther, FL, USA), a nano-electrospray ionization source 
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(Proxeon, Odense, Denmark) and a 10 m fused-silica 
emitter tip (New Objective, Inc., Woburn, MA, USA). Mass 
spectrometry data were processed using Protein Pilot soft-
ware (v.2.0, Applied Biosystems, Foster City, CA, USA). 
To identify and quantitate the relative amounts of adsorbed 
proteins, three stringent criteria were applied to the analysis: 
99.0% confidence in peptide identification; a change in rel-
ative binding of P0.01 to demonstrate significance; and a 
minimum of three distinct peptides detected for each protein 
identified. 
2  Results 
2.1  Protein adsorption and desorption 
The amount of total protein adsorbed to differentially modi-
fied latex particles (0–2 mmol L1; 2, 5 and 20 kD 
SC-mPEG) was quantified by colorimetric protein assay of 
supernatants containing latex desorbed proteins. As shown 
in Figure 2A, PEGylation of latex beads resulted in an 
mPEG dose-dependent decrease in total plasma protein ad-
sorption. SC-mPEG modified latex (2 mmol L1, 2 kD 
SC-mPEG) exhibited a dramatically decreased protein ad-
sorption relative to the bare latex control: (15.2±2.0) vs. 
(159.9±6.4) ng cm2, respectively. Moreover, low molecular 
weight polymers more effectively prevented protein adsorp-
tion than high molecular weight mPEG (e.g., 2 vs. 20 kD; 
0.1–2.0 mmol L1, P0.04). Specifically, 0.5 mmol L1 2 
kD mPEG resulted in (24.3±3.6) vs. (70.4±9.6) ng cm2 
obtained with the 20 kD polymer at the same grafting con-
centration. Finally, only grafted mPEG was capable of 
providing surface camouflage and preventing protein ad-
sorption. Latex particles incubated with soluble, non-acti-   
vated mPEG showed a similar degree of protein adsorption 
to that of bare latex.  
The observed decreased total protein adsorption and the 
dose and polymer length dependency of surface camouflage 
were further supported by the flow cytometry studies (Fig-
ure 2B). Differentially modified latex particles were incu-
bated with fluorescently labeled plasma and subjected to 
flow cytometry before and after protein desorption. The 
mean particle fluorescence of PEGylated latex was ex-
pressed relative to the fluorescence of unmodified latex that 
was normalized to 100%. These findings also demonstrated 
that the protein desorption process was effective at remov-
ing most but not all of the adsorbed species (Figure 2B). 
The values for fluorescent intensity of latex particles before 
vs. after protein desorption were dramatically decreased 
(e.g., 100.0% vs. 12.0%±2.1% for bare latex and 29.9%± 
3.8% vs. 4.7%±1.6% for 0.5 mmol L1, 5 kD SC-mPEG 
modified beads). Surprisingly, latex fluorescence following 
protein desorption from either bare or modified particles 
remained above that of the negative control (0%), suggest-
ing that desorption was incomplete.  
To further investigate decreased protein adsorption on 
PEGylated surfaces, proteins desorbed from differentially 
modified latex particles (0–2 mmol L1, 5 kD SC-mPEG) 
were analyzed by SDS-PAGE (Figure 3). As demonstrated 
above, absolute protein adsorption decreased dramatically, 
and in a grafting concentration dependent manner, in the 
PEGylated bead samples. Consistent with those findings, 
incubation of latex with unactivated (i.e., linker free) solu-
ble 5 kD mPEG (2.0 mmol L1) did not prevent protein ad-
sorption. The interaction of plasma proteins with control or 
PEGylated beads was further demonstrated microscopically 
using control and PEGylated 8.0 m latex beads incubated 
with Alexa Fluor 488-labeled human plasma. As shown in 
Figure 4, control beads avidly bound human plasma while 
the polymer grafted beads demonstrated a very significant  
 
 
Figure 2  PEGylation of 1.2 µm latex with SC-mPEG resulted in the dramatic reduction of the total amount of plasma protein adsorbed to the modified 
beads. Plasma protein-surface interactions were significantly inhibited by grafted mPEG in a dose-dependent manner as measured quantitatively by colori-
metric protein assay (A) and flow cytometry (B). Shorter polymers (2 kD) were shown to have increased efficacy of biophysical surface camouflage in com-
parison to the longer polymers (20 kD), especially at lower grafting concentrations. The protein desorption protocol resulted in a substantial but incomplete  
removal of all adsorbed species. 
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Figure 3  PEGylation of 1.2 m beads not only decreased total protein 
adsorption, but also resulted in a differential composition of adsorbed 
protein layer. SDS-PAGE analysis of proteins desorbed from differentially 
modified latex (0, 0.5, 2, 5 mmol L1 5 kD SC-mPEG) demonstrated a 
non-uniform decrease in protein band intensity. MW, Kaleidoscope mul-
ti-color molecular weight markers; Pl, 100 times diluted human plasma; 
Sol. 2.0, protein taken off latex incubated with soluble 2.0 mmol L1, 5 kD 
mPEG incapable of covalent binding. Protein was desorbed as described in 
Methods. The SDS-PAGE reflects a lower resolution analysis of protein  
adsorption versus that provided by iTRAQ analysis (Tables 1–4). 
 
Figure 4  Adsorption of Alexa Fluor 488-labeled human plasma to 8.0 
m latex beads was significantly (P<0.001) reduced by grafted polymer. 
Shown schematically and microscopically is the interaction of fluorescent-
ly tagged plasma proteins with the surface of control (A) or PEGylated (B) 
8.0 m latex beads. Photomicrographs: light microscopy image (upper  
panel); fluorescent microscopy image (lower panel). 
(P<0.0001) decrease in protein adsorption.  
2.2  iTRAQ analysis 
As shown in Figures 2 and 3, total protein adsorption to the 
PEGylated beads was dramatically reduced. However, as 
can be observed in Figure 3, not all proteins demonstrated a 
proportional decrease in adsorption to the PEGylated sam-
ples relative to the total decrease in adsorption. This was 
indicated by the variability and a non-uniform decrease in 
intensity of specific protein bands. This, visual observation 
indicated a differential protein composition of the adsorbed 
layer on PEGylated vs. bare latex surfaces. Thus, the com-
position and the relative abundance of specific proteins 
within the total adsorbed protein layer were studied by sub-
jecting desorbed protein samples to iTRAQ labeling and 
MS analysis [8]. For analytic analysis, the iTRAQ/MS pro-
tocol required that all the protein samples subjected to the 
labeling contain the same amount of total protein (100 g) 
in order to normalize the samples and avoid discrepancy 
during the MS analysis. Since the total protein adsorption 
was dramatically decreased on the PEGylated latex surface, 
iTRAQ analysis required 3, 9 and 15 times more of the 0.5, 
2.0 and 5.0 mmol L1 modified latex beads (1.2 m; 5 kD 
SC-mPEG) than the unmodified latex control in order to 
obtain the required 100 g of desorbed protein. 
The comparative MS analysis identified 95 protein spe-
cies adsorbed to the unmodified latex samples (Table 1). 
Because human plasma preparations contained low amounts 
of proteins derived from tissues and residual white cells, 
platelets and erythrocytes, a plasma protein subset consist-
ing of 47 proteins was identified. A second subset of 32 
immune regulatory plasma proteins was further delineated 
from this population based on well-characterized protein 
functions and consisted primarily of complement and coag-
ulation proteins as well as a small number of other proteins. 
The relative abundance of the desorbed protein within the 
total and plasma protein subsets differentially varied be-
tween bare and PEGylated beads. For the PEGylated (rela-
tive to bare) beads, 32 of the 47 plasma proteins demon-
strated decreased adsorption, five proteins exhibited a rela-
tive (to total) increase in abundance, while 10 remained 
unchanged when compared to the adsorbed protein compo-
sition of the bare latex control (Table 1). Moreover, of the 
immune regulatory plasma protein subset (32 proteins total), 
the majority exhibited a significant reduction in relative 
adsorption (Table 1; Figure 5).  
As demonstrated in Tables 2A–C, 68% of the plasma 
proteins exhibited significantly reduced relative adsorption 
to the PEGylated beads. Moreover, 62% of the immune 
regulatory proteins also exhibited decreased abundance (Fig-
ure 5; Table 2). Importantly, these proteins participate in the 
primary events related to the discrimination between “self” 
and “non-self” as well as activation of the immune system. 
Decreased relative adsorption of these pro-activating pro-
teins on foreign substrates is of primary importance and 
renders such surfaces “non-fouling” or “stealth”. For exam-
ple, prothrombin, fibrinogen, factor V and plasminogen 
activator inhibitor are important mediators of the coagula- 
Table 1  Summary of iTRAQ/MS Analysis. Shown are the numbers and 
the types of proteins demonstrating decreased, increased or unchanged 
abundances in the protein layer adsorbed to PEGylated beads (relative to 







Identified 95 47 32 
Decreased abundance on PEGylated surface 43 32 20 
Increased abundance on PEGylated surface 15 5 6 
Unchanged abundance on PEGylated surface 37 10 6 
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Figure 5  Complement and coagulation related proteins exhibited a pre-
dominant trend of significantly reduced adsorption. Data shown represents 
the percent change in adsorption (relative to unmodified latex) of the pro- 
teins listed in Tables 2–4. 
tion pathway. C4b, LPS binding protein, C1s, C1r, C3, C9 
and MASP-3 are potent activators of complement. De-
creased abundance on PEGylated surfaces was also ob-
served for proteins that serve inhibitory functions in the 
immune activation (e.g., plasminogen, C4b binding protein, 
vitamin K-dependent protein S and heparin cofactor II).  
In contrast, increased abundance on modified latex was 
noted for 5 (i.e., 10.6%) plasma proteins (Table 3). Four of 
these species are involved in immune regulation: C1q (alpha 
and beta chains), a fragment of a constant chain of IgG im-
munoglobulin, thrombospondin 1 and beta-2-glycoprotein. 
Finally, only 10 (i.e., 21.3%) plasma proteins (Table 4) 
demonstrated equivalent adsorption to both the PEGylated 
and unmodified beads. Most of these species serve homeo-
static functions, such as binding and transport, and include 
serum albumin, multimerin 1 and apolipoproteins A-V, C-II, 
C-III. Not unexpectedly, albumin constituted the vast ma-
jority of adsorbed protein in this group. Only four of the 10 
proteins are involved in immune regulation: C1q (C-chain),  
Table 2  Decreased relative plasma protein adsorption of coagulation-related, complement-related, and other proteins. Values presented are percent de-
crease in abundance on PEGylated latex beads (relative to unmodified beads). Proteins were identified and quantified by iTRAQ/MS analysisa) 
Accession MW (kD) pI Protein name 0.5 mmol L1 2 mmol L1 5 mmol L1 
Coagulation-related proteins       
IPI:IPI00019568.1 65.3 5.2 Prothrombin precursor 20.2## 55.4** 81.9* 
IPI:IPI00021885.1 75.5 5.1 Fibrinogen alpha/alpha-E chain precursor 56.4** 77.4* 77.7* 
IPI:IPI00298497.3 50.8 8.0 Fibrinogen beta chain precursor 51.3** 74.9* 75.3* 
IPI:IPI00019580.1 88.4 7.1 Plasminogen precursor 34.7# 74.4** 87.0* 
IPI:IPI00219713.1 48.5 5.2 Fibrinogen gamma chain precursor 53.7** 75.5* 75.5* 
IPI:IPI00294004.1 70.6 5.2 Vitamin K-dependent protein S precursor 0.0## 93.6* 95.5* 
IPI:IPI00478809.3 248.7 5.7 Coagulation factor V precursor 14.0## 42.8# 33.4# 
IPI:IPI00292950.3 55.0 6.3 Heparin cofactor II precursor 82.2* 94.6* 82.3* 
IPI:IPI00007118.1 42.8 7.0 Plasminogen activator inhibitor-1 precursor 13.5## 23.1# 51.5** 
IPI:IPI00216065.1 40.4 5.3 Vitamin K-dependent protein Z precursor 0.0## 36.0# 58.0** 
Complement-related proteins       
IPI:IPI00453459.1 192.8 6.9 Complement Component 4B preproprotein 83.4* 94.6* 94.5* 
IPI:IPI00021727.1 61.7 6.2 C4b-binding protein alpha chain precursor 71.4** 93.3* 93.6* 
IPI:IPI00400826.1 50.1 5.9 Clusterin 0.0## 21.2# 58.6** 
IPI:IPI00025862.1 26.4 5.0 C4b-binding protein beta chain precursor 80.4* 96.7* 97.6* 
IPI:IPI00017696.1 74.9 4.9 Complement C1s subcomponent precursor 0.0## 31.3# 57.9** 
IPI:IPI00164623.3 185.0 6.0 Complement C3 precursor 58.1** 75.5* 75.9* 
IPI:IPI00022395.1 61.0 5.4 Complement component C9 precursor 71.0** 89.4* 78.5* 
IPI:IPI00290283.5 81.9 5.0 Complement factor MASP-3 0.0## 59.5** 86.7* 
IPI:IPI00296165.5 78.3 5.8 Complement C1r subcomponent precursor 69.9** 90.7* 86.8* 
Other proteins       
IPI:IPI00022229.1 512.8 6.6 Apolipoprotein B-100 precursor 31.3# 82.2* 53.7** 
IPI:IPI00021841.1 28.1 5.3 Apolipoprotein A-I precursor 19.4## 51.2** 63.6** 
IPI:IPI00304273.1 43.4 5.2 Apolipoprotein A-IV precursor 29.8 51.2** 34.4# 
IPI:IPI00218192.1 101.2 6.2 Inter-alpha-trypsin inhibitor H4 precursor 50.1** 64.1** 57.1** 
IPI:IPI00514475.3 41.1 5.7 OTTHUMP00000028705 41.5# 62.3** 70.9** 
IPI:IPI00021842.1 34.2 5.5 Apolipoprotein E precursor 23.7# 43.6# 57.3** 
IPI:IPI00028413.3 69.4 5.0 Inter-alpha inhibitor H3 0.0## 81.9* 78.1* 
IPI:IPI00292530.1 71.4 6.3 Inter-alpha-trypsin inhibitor H1 precursor 78.2* 94.2* 84.2* 
IPI:IPI00305461.2 72.4 5.8 Inter-alpha-trypsin inhibitor H2 precursor 73.4** 88.1* 79.6* 
IPI:IPI00554598.1 23.8 4.8 Hypothetical protein DKFZp686N1868 0.0## 42.1# 77.9* 
IPI:IPI00298971.1 52.3 5.5 Vitronectin precursor 3.6## 43.4# 71.3** 
IPI:IPI00218732.2 39.6 5.1 Serum paraoxonase/arylesterase 1 0.0## 24.8# 54.1** 
IPI:IPI00032311.3 50.9 6.3 Lipopolysaccharide-binding protein precursor 70.9** 85.1* 54.3** 
a) Values are expressed as a percent decrease in protein abundance per 100 µg of total protein desorbed from PEGylated beads (relative to bare latex con-
trol). Percent decreased abundance labels: *, >75%; **, 50%–74.9%; #, 20%–49.9%; ##, <20%. Bold denotes immune-relevant proteins. IPI, international 
protein index; MW, molecular weight; kD, kilodaltons; pI, isoelectric point. 
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Table 3  Increase in relative plasma protein adsorption. Values presented are percent increase in abundance on PEGylated latex beads (relative to unmodi-
fied beads). Proteins were identified and quantified by iTRAQ/MS analysisa) 
Accession MW (kD) pI Protein name 
Percent increased adsorption 
Class 
0.5 mmol L1 2 mmol L1 5 mmol L1 
IPI:IPI00296099.3 127.5 4.7 Thrombospondin-1 precursor 5.2## 18.3## 26.3# E.C. matrix 
IPI:IPI00549769.1 36.1 8.5 Ig gamma-1 chain C region 20.0## 0.0## 89.9* Immune 
IPI:IPI00022392.1 23.7 9.3 Complement C1q,  chain precursor 0.0## 20.2## 34.4# Complement 
IPI:IPI00477992.1 23.7 8.9 
Complement component 1, q subcomponent, 
beta polypeptide 
0.0## 28.1# 60.4** Complement 
IPI:IPI00298828.1 36.3 8.4 Beta-2-glycoprotein I precursor 94.9* 55.2** 64.7** Coagulation 
a) Values are expressed as a percent increase in protein abundance per 100 µg of total protein desorbed from PEGylated beads (relative to bare latex con-
trol). Percent decreased abundance labels: *, >75%; **, 50%–74.9%; #, 20%–49.9%; ##, <20%. Bold denotes immune-relevant proteins. IPI, international 
protein index; MW, molecular weight; kD, kilodaltons; pI, isoelectric point. 
Table 4  Unchanged relative plasma protein adsorption. Plasma proteins exhibiting unchanged abundance on PEGylated latex (relative to unmodified 
beads). Proteins were identified and quantitated by iTRAQ/MS analysisa) 
Accession MW (kD) pI Protein name Class 
IPI:IPI00022434.1 66.5 5.7 Serum albumin precursor Transport 
IPI:IPI00303283.1 84.4 5.0 Integrin beta-3 precursor Receptor 
IPI:IPI00418392.1 136.1 7.9 Multimerin 1 Transport 
IPI:IPI00022394.2 22.8 8.3 Complement C1q subcomponent, C chain precursor Complement 
IPI:IPI00023014.1 225.7 5.4 Von Willebrand factor precursor Coagulation 
IPI:IPI00465378.1 38.9 6.0 Apolipoprotein A-V precursor Transport 
IPI:IPI00021857.1 8.8 4.7 Apolipoprotein C-III precursor Transport 
IPI:IPI00022445.1 10.3 9.0 Platelet basic protein precursor Immune 
IPI:IPI00022446.1 7.8 8.8 Platelet factor 4 precursor Coagulation 
IPI:IPI00021856.3 8.9 4.7 Apolipoprotein C-II precursor Transport 
a) Although there was no difference in the relative abundance of the above-listed species per 100 µg total desorbed protein solution from either bare or 
modified latex, the total adsorption to PEGylated surfaces decreased dramatically from that of unmodified beads, e.g., (18.3±4.1) (2 mmol L1, 5 kD 
SC-mPEG) vs. (159.9±6.4) ng cm2 (bare latex). Bold denotes immune-relevant proteins. IPI, international protein index; MW, molecular weight; kD, kilo-
daltons; pI, isoelectric point. 
 
Von Willebrand factor, platelet basic protein and platelet 
factor 4. 
3  Discussion 
Immunologic recognition of foreign materials and cells is 
highly dependent on cell surface interactions with either 
soluble factors (e.g., antibody binding or denaturation of 
plasma proteins) and/or recognition by cellular components 
of the immune system (e.g., antigen presenting cells and 
lymphocytes). Previous studies have demonstrated that eas-
ily denatured (i.e., “soft”) proteins are capable of unfolding 
and binding to hydrophobic surfaces via multiple contacts 
upon exposure of internal hydrophobic residues. This leads 
to very strong adhesion through additional H-bonds, hy-
drophobic, charge-charge and Van der Waals interactions 
[9,10]. The use of grafted polymers to immunocamouflage 
the surface of implanted biomaterials, transplanted tissues 
or transfused cells targets this initial, and crucial, step in the 
process of inflammation and allorecognition in a manner 
that is applicable to a broad range of clinical scenarios.  
In this study, a latex bead model was utilized to examine 
the binding of plasma proteins to PEGylated surfaces. The 
covalent grafting of mPEG to latex particles resulted in a 
significant decrease in surface-macromolecule interactions 
(Figures 2–5) resulting in the global immunocamouflage of 
the particles, as indicated by the decreased total plasma 
protein adsorption. However, in contrast to previous bio-
logical studies, the biophysical latex model together with 
the application of MS-based proteomics allowed for the 
quantitative and qualitative estimations of total as well as 
specific surface interactions inhibited by PEGylation, aiding 
in the further elucidation of biological responses to 
PEGylated surfaces.  
mPEG is a highly flexible, hydrophilic polymer occupy-
ing a large 3D space (i.e., possessing a large exclusion 
volume) and can dramatically alter the characteristics of any 
surface it is bound to (Figure 6A). Chemically, due to the 
highly hydrophilic nature of mPEG and its extensive water 
binding properties, PEGylation results in increased surface 
hydrophilicity of the latex particles [11]. Previous studies 
have shown that hydrophilic surfaces have decreased total 
protein adsorption and are also more biocompatible [12]. 
Thus, mPEG grafting generates a steric barrier while simul-
taneously biophysically camouflaging surface charge thus 
reducing immune recognition of implantable biomaterials, 
allogeneic red blood cells [5,13–18], lymphocytes [3,4,19–21]  
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Figure 6  The reduced interaction of plasma proteins with latex beads is highly predictive of the biological utility of immunocamouflage. Not only can 
grafted polymers prevent unwanted adsorption of plasma proteins to biomaterials (e.g., vascular stents), they can also prevent or attenuate undesirable bio-
logical interactions. A, The covalent grafting of polymers (e.g., mPEG or HPG) resulted in the biophysical camouflage of surface proteins (e.g., cell recep-
tors, antigenic site and viral binding sites). This was accomplished via both a steric barrier and charge camouflage. B, Consequent to this biophysical barrier, 
RBC exhibited reduced antibody binding to blood group antigens (e.g., Kell, k). C, Immunocamouflage of lymphocytes resulted in the loss of allorecognition 
of MHC disparate cells as demonstrated by attenuated proliferation in mixed lymphocyte reactions (MLR). D, The immunocamouflage of viral receptors  
located on the membrane surface of host cells reduced viral invasion, proliferation and disease progression. 
 
and viruses (Figure 6BD) [22]. As shown in this study, 
consequent to PEGylation, latex particles demonstrated sig-
nificant inhibition of protein adsorption in a polymer dose- 
and length-dependent manner, as measured quantitatively 
with colorimetric protein assay and flow cytometry (Figure 
2A and B) and qualitatively by SDS-PAGE, fluorescent 
microscopy and iTRAQ-MS analysis (Figures 3–5).  
The inhibition of plasma protein adsorption to latex 
beads was effected by changes in thermodynamics of the 
latex-plasma interface mediated by charge camouflage and, 
most notably, the steric exclusion effect of the grafted 
mPEG polymers. Steric effects were increased when poly-
mers were grafted at higher density, particularly by short 
chain polymers (e.g., 2 kD) that can be grafted at a higher 
density (Figure 2A and B). In contrast to the lower molecu-
lar weight polymers, high density grafting of long chain 
polymers is inhibited via steric self-exclusion effects arising 
from the initial population of grafted polymers.  
Biophysically, the steric hindrance arose due to de-
creased conformational freedom of the grafted mPEG pol-
ymer resulting in decreased entropy of the polymers. When 
macromolecules interact with mPEG-modified surfaces, 
they contact and compress the polymer chains resulting in a 
further decrease in entropy. This highly thermodynamically 
unfavorable state is then reduced by the rejection of mole-
cules from the polymer contact points thereby preventing 
protein adsorption and increasing entropy and conforma-
tional freedom of the polymer chains [23–25]. At higher 
surface polymer densities, (Figures 2 and 3) chains are even 
more restricted in conformational freedom thereby increas-
ing plasma protein rejection from the biomaterial (bead) 
surface.  
As evidenced by the iTRAQ/MS studies (Tables 1–4), 
68% of all identified plasma proteins exhibited reduced 
binding to PEGylated surfaces. Of those proteins showing 
reduced adsorption, the amount of bound protein reduced 
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was dependent on mPEG grafting concentration. For exam-
ple, as shown in Table 2, 0.5, 2 and 5 mmol L1 grafting 
concentrations resulted in 12.5%, 50% and 56% of the iden-
tified proteins showing a 75% decreased abundance in 
comparison to bare latex control. As demonstrated in Table 
2, decreased adsorption of multiple immune proteins in-
volved in allorecognition, coagulation and complement ac-
tivation (e.g., plasminogen, C4b binding protein, vitronectin, 
vitamin K-dependent protein S, and heparin cofactor II) was 
noted. The observed reduction of adsorbed protein coupled 
with the increased hydrophilicity of PEGylated surfaces is 
also potentially beneficial as these surfaces are less throm-
bogenic than surfaces with adsorbed, partially denatured 
proteins and/or hydrophobic surfaces. Indeed, the propensi-
ty of hydrophobic surfaces to be thrombogenic is partially 
derived from the increased avidity for, adsorption of, and 
denaturation of plasma proteins.  
A sparingly small number of proteins (Tables 1 and 3) 
exhibited a relative increase in adsorption or interaction 
with the PEGylated bead surface. Interestingly, these pro-
teins were collagen or fibrin-like proteins, or proteins in-
volved in adhesion and binding of collagen-like proteins. 
However, while small in number, these proteins are active 
components of the immune system and did demonstrate an 
mPEG-dose dependent increase in adsorption. Included 
among these proteins were components of the C1q complex 
(alpha and beta chains) that is capable of initiating comple-
ment activation. The C1q (alpha and beta chains) protein 
interacts with the constant chain of IgG [26,27] and both 
could become bound to the PEGylated surfaces due to 
C1q’s collagen-like structure [28]. However, previous stud-
ies have demonstrated no direct complement activation or 
consumption by mPEG-modified human erythrocytes [15]. 
The increased relative abundance of thrombospondin 1 
likely arose due to its complex multi-domain structure that 
allows it to interact with cell-adhesive receptors and glyco-
proteins, including fibronectin and collagen [29]. Finally, 
not all adsorbed protein would be detrimental. The binding 
of beta-2-glycoprotein I precursor and thrombospondin 
could potentially serve beneficial functions in cell and tissue 
transplantation. Beta-2-glycoprotein binds to negatively 
charged phospholipids and inhibits the coagulation cascade 
[30,31], while thrombospondin-1 is a potent inhibitor of 
T-cell and dendritic cell activation [32,33]. 
Of the 10 proteins (Table 4) that exhibited no relative 
change in abundance, the majority serve homeostatic func-
tions (e.g., binding and transport). Only four proteins from 
this subset have immunological roles: C1q (c-chain), Von 
Willebrand factor, platelet basic protein and platelet factor 4. 
The c-chain of C1q is responsible for binding of the C1q 
complex while Von Willebrand factor acts as a chaperone 
for coagulation factor VIII; thus in addition to their roles as 
immune-related proteins, both fall into the subset of binding 
and transport proteins. Platelet factor 4 and platelet basic 
protein belong to the family of chemokines responsible for 
down-regulation of immunological response. Platelet factor 
4 inhibits lymphocyte proliferation and cytokine release 
[34]. Platelet basic protein was shown to decrease chemo-
taxis and function of neutrophils in pro-inflammatory re-
sponse [35]. In addition, as chemokines are signaling pro-
teins, in the absence of binding to their receptors these pro-
teins would, most likely, not exert any biological effects. 
Thus, none of these proteins are implicated in the activation 
of the immune system and their adsorption should not result 
in adverse immune reactions.  
Our proteomic findings are both predictive of, and sup-
ported by, biological observations. As demonstrated in Fig-
ure 6, polymer grafting to intact cells prevented or attenu-
ated immunologically undesirable biological interactions. 
As schematically presented in Figure 6A, the covalent 
grafting of polymers (e.g., mPEG or HPG) results in the 
biophysical camouflage of surface proteins (e.g., cell re-
ceptors, antigenic sites and viral binding sites). Consequent 
to the formation of this biophysical barrier: human erythro-
cytes exhibit reduced antibody binding to blood group anti-
gens (e.g., Kell (k)) (Figure 6B); allorecognition of HLA 
disparate lymphocytes is attenuated as demonstrated by loss 
of proliferation in mixed lymphocyte reactions (MLR) 
(Figure 6C); and viral receptors located on the membrane 
surface of host cells are immunocamouflaged resulting in 
reduced viral invasion, proliferation and disease progression 
(Figure 6D). In aggregate, the biophysical, proteomic and 
biological studies all support the potential utility of im-
munocamouflage in biomaterials and modified cells/tissue 
in clinical medicine.  
In summary, covalent grafting of mPEG to latex beads 
gave rise to the global immunocamouflage of the bead sur-
face resulting in decreased plasma protein adsorption as 
assessed by both qualitative and quantitative protein anal-
yses (Figure 7). The reduction in plasma adsorption arises 
consequent to thermodynamic steric exclusion and charge 
camouflage effects of the grafted polymer. Moreover, quan-
titative proteomic studies demonstrated that latex bead 
modification significantly prevented surface interactions 
with plasma proteins involved in immune recognition of 
biomaterials and allogeneic cells and tissues. Biologically, 
the reduced, adverse, surface-macromolecule interactions 
theoretically should enhance biocompatibility by preventing 
the generation of immune recognition signals (e.g., dena-
tured proteins or immunoglobulin binding). Indeed, these 
latex bead biocompatibility studies are supportive and pre-
dictive of our previously reported biologic observations 
(Figure 6). The knowledge derived from these proteomic 
studies will help further define the physical and chemical 
parameters for PEGylation (or other polymers) of bio-
materials and allogeneic cells and tissues in order to pre-
cisely control the extent and specificity of fluid-surface (e.g., 
plasma-implantable material), cell-cell and cell-macromo-    
lecule interactions. The practical application of the im-
munocamouflage technology could have significant impact 
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on improving the safety of implantable biomaterials as well 




Figure 7  Qualitative and quantitative analysis of plasma surface interac-
tions demonstrated the efficacy of immunocamouflage in preventing pro-
tein adsorption. Moreover, iTRAQ analysis provided clear evidence for 
reduced adsorption of proteins associated with immunological recognition  
of foreign cells/tissues and biomaterials. 
The authors thank Drs. Peter Schubert (Canadian Blood Services and 
University of British Columbia, Vancouver, BC, Canada) and Jurgen Kast 
(University of British Columbia, Biomedical Research Centre, Vancouver, 
BC, Canada) for their helpful comments in the manuscript preparation. In 
addition, we acknowledge Mr. Derek Smith (University of Victoria, Ge-
nome BC Proteomics Centre, Victoria, BC, Canada) for his technical as-
sistance and expertise and Dr. Geraldine Walsh, CBS Scientific Writer, for 
writing and editorial assistance. This work was supported by grants from 
the Canadian Blood Services, Canadian Blood Services-Canadian Insti-
tutes of Health Research (CBS-CIHR) Partnership Fund and Health Can-
ada. The views expressed herein do not necessarily represent the view of 
the federal government of Canada. We thank the Canada Foundation for 
Innovation and the Michael Smith Foundation for Health Research for 
infrastructure funding at the University of British Columbia Centre for 
Blood Research.  
1 Gallagher W M, Lynch I, Allen L T, et al. Molecular basis of 
cell-biomaterial interaction: insights gained from transcriptomic and 
proteomic studies. Biomaterials, 2006, 27: 5871–5882 
2 Ratner B D, Bryant S J. Biomaterials: where we have been and where 
we are going. Annu Rev Biomed Eng, 2004, 6: 41–75 
3 Chen A M, Scott M D. Current and future applications of immuno-
logical attenuation via pegylation of cells and tissue. BioDrugs, 2001, 
15: 833–847 
4 Chen A M, Scott M D. Comparative analysis of polymer and linker 
chemistries on the efficacy of immunocamouflage of murine leuko-
cytes. Artif Cells Blood Substit Immobil Biotechnol, 2006, 34: 
305–322 
5 Scott M D, Murad K L, Koumpouras F, et al. Chemical camouflage 
of antigenic determinants: stealth erythrocytes. Proc Natl Acad Sci 
USA, 1997, 94: 7566–7571 
6 Sutton T C, Scott M D. The effect of grafted methoxypoly(ethylene 
glycol) chain length on the inhibition of respiratory syncytial virus 
(RSV) infection and proliferation. Biomaterials, 2010, 31: 4223– 
4230 
7 Laemmli U K. Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature, 1970, 227: 680–685 
8 Ross P L, Huang Y N, Marchese J N, et al. Multiplexed protein 
quantitation in Saccharomyces cerevisiae using amine-reactive iso-
baric tagging reagents. Mol Cell Proteomics, 2004, 3: 1154–1169 
9 Vroman L. Effect of absorbed proteins on the wettability of hydro-
philic and hydrophobic solids. Nature, 1962, 196: 476–477 
10 Horbett T A. Mass action effects on competitive adsorption of fi-
brinogen from hemoglobin solutions and from plasma. Thromb 
Haemost, 1984, 51: 174–181 
11 Harris J M. Introduction to biotechnical and biomedical applications 
of poly(ethylene glycol). In: Harris M J, ed. Topics in Applied 
Chemistry. New York: Plenum Press, 1992. 1-14 
12 Andrade J D. Interfacial phenomena and biomaterials. Med Instrum, 
1973, 7: 110–119 
13 Bradley A J, Murad K L, Regan K L, et al. Biophysical consequences 
of linker chemistry and polymer size on stealth erythrocytes: size 
does matter. Biochim Biophys Acta, 2002, 1561: 147–158 
14 Murad K L, Mahany K L, Brugnara C, et al. Structural and functional 
consequences of antigenic modulation of red blood cells with meth-
oxypoly(ethylene glycol). Blood, 1999, 93: 2121–2127 
15 Bradley A J, Test S T, Murad K L, et al. Interactions of IgM ABO 
antibodies and complement with methoxy-PEG-modified human 
RBCs. Transfusion, 2001, 41: 1225–1233 
16 Scott M D, Chen A M. Beyond the red cell: pegylation of other blood 
cells and tissues. Transfus Clin Biol, 2004, 11: 40–46 
17 Bradley A J, Scott M D. Separation and purification of methoxy-
poly(ethylene glycol) grafted red blood cells via two-phase partition-
ing. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 807: 
163–168 
18 Bradley A J, Scott M D. Immune complex binding by immunocam-
ouflaged [poly(ethylene glycol)-grafted] erythrocytes. Am J Hematol, 
2007, 82: 970–975 
19 Murad K L, Gosselin E J, Eaton J W, et al. Stealth cells: prevention 
of major histocompatibility complex class II-mediated T-cell activa-
tion by cell surface modification. Blood, 1999, 94: 2135–2141 
20 Chen A M, Scott M D. Immunocamouflage: prevention of transfu-
sion-induced graft-versus-host disease via polymer grafting of donor 
cells. J Biomed Mater Res A, 2003, 67: 626–636 
21 Scott M D, Murad K L. Cellular camouflage: fooling the immune 
system with polymers. Curr Pharm Des, 1998, 4: 423–438 
22 McCoy L L, Scott M D. Broad-spectrum antiviral porphylaxis: inhi-
bition of viral infection by polymer grafting with methoxy-
poly(ethylene glycol). In: Torrence P F, ed. Antiviral Drug Discovery 
for Emerging Diseases and Bioterrorism Threats. New York: John 
Wiley & Sons, Inc., 2005. 379–395 
23 Szleifer I. Protein adsorption on surfaces with grafted polymers: a 
theoretical approach. Biophys J, 1997, 72: 595–612 
24 Hermans J. Excluded-volume theory of polymer-protein interactions 
based on polymer chain statistics. J Chem Phys, 1982, 77: 2193–2203 
25 Brooks D E, Haynes C A, Hritcu D, et al. Size exclusion chromatog-
raphy does not require pores. Proc Natl Acad Sci USA, 2000, 97: 
7064–7067 
26 Yasmeen D, Ellerson J R, Dorrington K J, et al. The structure and 
function of immunoglobulin domains. IV. The distribution of some 
effector functions among the Cgamma2 and Cgamma3 homology re-
gions of human immunoglobulin G1. J Immunol, 1976, 116: 518–526 
27 Colomb M, Porter R R. Characterization of a plasmin-digest frag-
ment of rabbit immunoglobulin gamma that binds antigen and com-
plement. Biochem J, 1975, 145: 177–183 
28 Reid K B. Complete amino acid sequences of the three collagen-like 
regions present in subcomponent C1q of the first component of hu-
man complement. Biochem J, 1979, 179: 367–371 
29 Lawler J, Duquette M, Urry L, et al. The evolution of the thrombos-
pondin gene family. J Mol Evol, 1993, 36: 509–516 
30 Miyakis S, Giannakopoulos B, Krilis S A. Beta 2 glycoprotein 
I––function in health and disease. Thromb Res, 2004, 114: 335–346 
31 Brighton T A, Hogg P J, Dai Y P, et al. Beta 2-glycoprotein I in 
 Le Y, et al.   Sci China Life Sci   March (2012) Vol.55 No.3 201 
thrombosis: evidence for a role as a natural anticoagulant. Br J Hae-
matol, 1996, 93: 185–194 
32 Doyen V, Rubio M, Braun D, et al. Thrombospondin 1 is an auto-
crine negative regulator of human dendritic cell activation. J Exp 
Med, 2003, 198: 1277–1283 
33 Li Z, He L, Wilson K, et al. Thrombospondin-1 inhibits TCR-    
mediated T lymphocyte early activation. J Immunol, 2001, 166: 
2427–2436 
34 Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 in-
hibits proliferation and cytokine release of activated human T cells. J 
Immunol, 2002, 169: 770–777 
35 Ehlert J E, Ludwig A, Grimm T A, et al. Down-regulation of neutro-
phil functions by the ELR(+) CXC chemokine platelet basic protein. 
Blood, 2000, 96: 2965–2972 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
 
